The FDA has agreed to commence a formal review of Moderna’s application for its experimental seasonal flu shot, marking a significant shift in the agency's previous stance. The turnaround followed an agreement by the biotechnology firm to conduct additional clinical testing specifically targeting elderly populations. The news sparked a rally in Moderna shares, providing a lift to the broader sector as investors interpreted the move as a sign of regulatory flexibility.

Scaling Advanced Manufacturing

In a separate boost to the industry, Johnson & Johnson confirmed it will invest more than $1 billion to develop a next-generation cell therapy production site. The facility, located in Montgomery County, Pennsylvania, is intended to bolster the company's capacity for complex biologics and precision medicine.

The investment underscores a strategic push by major pharmaceutical players to secure domestic supply chains for high-tech therapies. By establishing dedicated infrastructure for cell-based treatments, the company aims to streamline the commercialization of its oncology and immunology pipelines.